- Home
- ESAB vs RYTM Comparison
ESAB vs RYTM Comparison
Compare ESAB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | RYTM |
|---|---|---|
| Founded | 1904 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.8B |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ESAB | RYTM |
|---|---|---|
| Price | $74.05 | $105.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $138.56 | $131.14 |
| AVG Volume (30 Days) | ★ 750.2K | 613.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $2,842,555,000.00 | N/A |
| Revenue This Year | $6.21 | $55.34 |
| Revenue Next Year | $5.33 | $86.06 |
| P/E Ratio | $59.35 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $74.69 | $74.50 |
| 52 Week High | $137.42 | $122.20 |
Technical Indicators
Market Signals| Indicator | ESAB | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 43.23 |
| Support Level | N/A | $99.14 |
| Resistance Level | $106.33 | $111.56 |
| Average True Range (ATR) | 2.86 | 4.17 |
| MACD | -0.58 | -1.15 |
| Stochastic Oscillator | 8.40 | 15.66 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2025.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.